Drug Profile
Research programme: progenitor cell activators - Korro Bio
Latest Information Update: 11 Jan 2024
Price :
$50
*
At a glance
- Originator Frequency Therapeutics
- Developer Harvard University; Korro Bio; US Army Institute of Surgical Research
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Multiple sclerosis
- No development reported Musculoskeletal disorders; Noise-induced hearing loss; Type 1 diabetes mellitus
Most Recent Events
- 10 Mar 2023 Preclinical trials in Multiple sclerosis in USA (unspecified route)
- 28 Mar 2022 No recent reports of development identified for preclinical development in Musculoskeletal-disorders in USA
- 28 Mar 2022 No recent reports of development identified for research development in Type-1 diabetes mellitus in USA